Entonox
PreclinicalSmall molecule
Entonox is one of 72 small molecule programs targeting Cognition. It is currently in Preclinical.
3
Indications
5
Total Trials
2
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
88 competitors in Cognition
#DrugCompanyPhaseTrials
1Vyvanse
TakedaApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Accutane
CConrado Roberto Hoffmann Filho
Approved
Zocor
OOrganon and Co
Approved
Namenda
AbbViePhase 3
Metaxalone
VViking Therapeutics, Inc.
Approved
Epidiolex
Jazz PharmaceuticalsPhase 2
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 2
Remimazolam Tosilate
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Psilocybin
COMPASS PathwaysPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sedation1 trial
A Single-centre Study of Entonox Versus Midazolam Sedation in Gastroscopy
Terminated·—·Phase 4·NCT01744184·62 enrolled
Women1 trial
The Effect of Entonox on Stages of Labor in Nulliparous Women
Completed·DDepartment of Medical Services Ministry of Public Health of Thailand·N/A·NCT04321642·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Entonox. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details